APA (7th ed.) Citation

L, S., G, V., & KN, C. (2026). Podocyte-Targeted Therapy in Focal Segmental Glomerulosclerosis: Insights From a Phase 2 Trial of TRPC6 Inhibition. American journal of kidney diseases : the official journal of the National Kidney Foundation, 88(1), 166. https://doi.org/10.1053/j.ajkd.2026.04.006

Chicago Style (17th ed.) Citation

L, Sanchez-Russo, Vasquez-Rios G, and Campbell KN. "Podocyte-Targeted Therapy in Focal Segmental Glomerulosclerosis: Insights From a Phase 2 Trial of TRPC6 Inhibition." American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation 88, no. 1 (2026): 166. https://doi.org/10.1053/j.ajkd.2026.04.006.

MLA (9th ed.) Citation

L, Sanchez-Russo, et al. "Podocyte-Targeted Therapy in Focal Segmental Glomerulosclerosis: Insights From a Phase 2 Trial of TRPC6 Inhibition." American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation, vol. 88, no. 1, 2026, p. 166, https://doi.org/10.1053/j.ajkd.2026.04.006.